DE60112310D1 - Das hydrochloridsalz des 5[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dions - Google Patents

Das hydrochloridsalz des 5[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dions

Info

Publication number
DE60112310D1
DE60112310D1 DE60112310T DE60112310T DE60112310D1 DE 60112310 D1 DE60112310 D1 DE 60112310D1 DE 60112310 T DE60112310 T DE 60112310T DE 60112310 T DE60112310 T DE 60112310T DE 60112310 D1 DE60112310 D1 DE 60112310D1
Authority
DE
Germany
Prior art keywords
dion
thiazolidine
pyridyl
ethoxy
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60112310T
Other languages
English (en)
Other versions
DE60112310T2 (de
Inventor
Andrew Simon Craig
Michael Millan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of DE60112310D1 publication Critical patent/DE60112310D1/de
Application granted granted Critical
Publication of DE60112310T2 publication Critical patent/DE60112310T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60112310T 2000-09-06 2001-09-05 Das Hydrochloridsalz von 5-[4-[2-(N-Methyl-N-(2-Pyridyl)Amino)Ethoxy]BenzylThiazolidin-2,4-Dion Expired - Lifetime DE60112310T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0021865 2000-09-06
GBGB0021865.1A GB0021865D0 (en) 2000-09-06 2000-09-06 Novel pharmaceutical
PCT/GB2001/003991 WO2002020519A1 (en) 2000-09-06 2001-09-05 The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (2)

Publication Number Publication Date
DE60112310D1 true DE60112310D1 (de) 2005-09-01
DE60112310T2 DE60112310T2 (de) 2006-02-09

Family

ID=9898953

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60112310T Expired - Lifetime DE60112310T2 (de) 2000-09-06 2001-09-05 Das Hydrochloridsalz von 5-[4-[2-(N-Methyl-N-(2-Pyridyl)Amino)Ethoxy]BenzylThiazolidin-2,4-Dion

Country Status (35)

Country Link
US (3) US20040034066A1 (de)
EP (1) EP1315723B1 (de)
JP (1) JP2004508369A (de)
KR (1) KR100770513B1 (de)
CN (1) CN100558717C (de)
AP (1) AP1715A (de)
AT (1) ATE300538T1 (de)
AU (2) AU8428401A (de)
BG (1) BG107607A (de)
BR (1) BR0113713A (de)
CA (1) CA2421213A1 (de)
CY (1) CY1105252T1 (de)
CZ (1) CZ302125B6 (de)
DE (1) DE60112310T2 (de)
DK (1) DK1315723T3 (de)
DZ (1) DZ3475A1 (de)
EA (1) EA004296B1 (de)
EC (1) ECSP034505A (de)
ES (1) ES2244647T3 (de)
GB (1) GB0021865D0 (de)
HK (1) HK1057749A1 (de)
HU (1) HUP0300938A3 (de)
IL (2) IL154724A0 (de)
MA (1) MA25908A1 (de)
MX (1) MXPA03001956A (de)
NO (1) NO324020B1 (de)
NZ (1) NZ524548A (de)
OA (1) OA12375A (de)
PL (1) PL360578A1 (de)
PT (1) PT1315723E (de)
SI (1) SI1315723T1 (de)
SK (1) SK2632003A3 (de)
UA (1) UA74003C2 (de)
WO (1) WO2002020519A1 (de)
ZA (1) ZA200301809B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
DE102005034406A1 (de) * 2005-07-22 2007-02-01 Ratiopharm Gmbh Neue Salze von Rosiglitazon
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
JP5063714B2 (ja) * 2010-01-29 2012-10-31 シャープ株式会社 画像読取装置及び画像形成装置
EP2508525A1 (de) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituierte 2,3-Dihydroimidazo[1,2-c]chinazolinsalze
RU2487132C1 (ru) * 2012-07-23 2013-07-10 Общество с ограниченной ответственностью "Метаген" Производные циклических 5-нитропиридин-2-ил-тиоалкенил-4-дитиокарбаматов, обладающие противогрибковой активностью, и их применение

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
DK0896182T3 (da) * 1997-07-17 2002-07-29 Interlemo Holding Sa Sammenkoblingssystem
CN1183130C (zh) * 1999-09-24 2005-01-05 中国人民解放军军事医学科学院毒物药物研究所 噻唑烷类衍生物及其医药用途
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Also Published As

Publication number Publication date
US20070191435A1 (en) 2007-08-16
KR100770513B1 (ko) 2007-10-25
AU2001284284B2 (en) 2005-08-04
IL154724A0 (en) 2003-10-31
OA12375A (en) 2004-03-19
MXPA03001956A (es) 2003-06-24
ATE300538T1 (de) 2005-08-15
WO2002020519A1 (en) 2002-03-14
HUP0300938A2 (hu) 2003-11-28
MA25908A1 (fr) 2003-10-01
HK1057749A1 (en) 2004-04-16
SI1315723T1 (en) 2005-10-31
AP2003002758A0 (en) 2003-06-30
EA200300345A1 (ru) 2003-08-28
DK1315723T3 (da) 2005-10-24
BR0113713A (pt) 2004-07-06
NO20031020L (no) 2003-05-06
AU8428401A (en) 2002-03-22
UA74003C2 (en) 2005-10-17
ZA200301809B (en) 2004-04-19
CZ2003615A3 (cs) 2003-11-12
PL360578A1 (en) 2004-09-06
IL154724A (en) 2009-07-20
NO324020B1 (no) 2007-07-30
NO20031020D0 (no) 2003-03-05
BG107607A (bg) 2003-12-31
EA004296B1 (ru) 2004-02-26
DE60112310T2 (de) 2006-02-09
DZ3475A1 (fr) 2002-03-14
KR20030027118A (ko) 2003-04-03
NZ524548A (en) 2004-10-29
HUP0300938A3 (en) 2005-04-28
CY1105252T1 (el) 2010-03-03
US20050282867A1 (en) 2005-12-22
EP1315723A1 (de) 2003-06-04
PT1315723E (pt) 2005-11-30
SK2632003A3 (en) 2003-12-02
CA2421213A1 (en) 2002-03-14
CZ302125B6 (cs) 2010-11-03
CN1366520A (zh) 2002-08-28
JP2004508369A (ja) 2004-03-18
ECSP034505A (es) 2003-06-25
ES2244647T3 (es) 2005-12-16
AP1715A (en) 2007-02-28
CN100558717C (zh) 2009-11-11
EP1315723B1 (de) 2005-07-27
GB0021865D0 (en) 2000-10-18
US20040034066A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
DE60112729D1 (de) Hcl-salze von 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dion
DE60004196D1 (de) Polymorph von 5-[4-[2-(n-methyl-n-(2-pyrdyl)amino)äthoxy]benzyl]thiazolidin-2,4-dion, maleinsäuresalz
NO20031356L (no) Nye polymorfe former av 5-[4-[2-[N-metyl-N-(2- pyridyl]amino]etoksy]benzyl]tiazolidin-2,4-dionmaleat og fremgangsmåte for fremstilling avsamme
NO2009002I1 (no) 5-{4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl}tiazolidin-2,4-dionmaleat(salter/solvater)+glimepirid
NO20003069D0 (no) 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl]tiazolidin- 2,4-dion-maleinsyre-salt-hydrat som farmasøytikum
DE60112310D1 (de) Das hydrochloridsalz des 5[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dions
IL188116A0 (en) Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione
DK1446404T3 (da) Rosiglitazonedisylater og deres anvendelse som antidiabetika
IL153280A0 (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4 dione hydriodide as pharmaceutical
SI1265893T1 (sl) Hidrokloridne soli 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil)tiazolidin-2,4-diona
AU2002222305A1 (en) 5-'4-'2-(n-methyl-n- (2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione mesylate salt

Legal Events

Date Code Title Description
8364 No opposition during term of opposition